Viridian RIA’s Biogen BIIB Stock Holding History

Viridian RIA’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$283	–	93
2021 Q3	$283	Buy	+100	New	+$32.8K	0.07%	14

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Viridian RIA's BIIB Position: Q4 2021 in Review

Viridian RIA sold out of Biogen (BIIB) in Q4 2021, closing a stake of 100 shares — an estimated $283 sold.

Viridian RIA first reported a position in BIIB in Q3 2021 and held it in 1 quarter. The position peaked at $283 in Q3 2021. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Viridian RIA reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Viridian RIA sold 100 Biogen shares in Q4 2021, an estimated $283.
Viridian RIA first reported a position in Biogen in Q3 2021 and held it in 1 quarter.
Viridian RIA's Biogen position peaked at $283 in Q3 2021.
1,010 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Viridian RIA's 13F filing for Q4 2021, filed 14 Jan 2022.